ATEC
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Alphatec Holdings, Inc.
- Nom
- Alphatec Holdings, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $1.7B
- Employés
- 913
- PDG
- Patrick S. Miles
- Site web
- https://www.atecspine.com
- Marché
- GMEDIARTOFIXSNNSYKXTNT
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 115 000 titres (~1 013 150,00 $ US)
- Insiders
- Miles Patrick
- Total bought
-
$1,013,150
Avg buy (VWAP, 90d window) $8.81 vs last close $11.11 (+26.1%)
- Total sold
-
$78,821
Avg sell (VWAP, 90d window) $9.65 vs last close $11.11 (+15.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$78,821 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-10
- Liquidity
- Liquid $24,493,004/day · 20d vol
- Last synced
-
2026-10-23 21:10:10
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-10 | Miles Patrick | Buy · P | 115,000 | $8.81 | $1,013,150 | Form 4 |
| 2026-08-05 | Marshall Tyson Eliot | Sell · S · 10b5-1 | 8,168 | $9.65 | $78,821 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
The CEO's $1M cluster buy following a 42% decline is a meaningful insider conviction signal ahead of Q3 earnings, supporting a cautious watch stance.
The first sentence of the analysis written for ATEC on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 2.06 · operating margin -11% — readings disagree
Suggested stop 10.41, nearest stored support minus 0.5 ATR(6.3% under the last close). Reward/risk to the next stored resistance is 0.61. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 ATEC to Report Third Quarter 2026 Financial Results on October 29, 2026 CARLSBAD, Calif--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2026 financial results on October 29, 2026, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET.WebcastTo access the live webcast, please use this link or visit the Events & Presentations section of ATEC''s Investor Relations web.
- 2026-10-01 Reviewing LogicMark (OTCMKTS:LGMKD) & Alphatec (NASDAQ:ATEC) Alphatec (NASDAQ: ATEC - Get Free Report) and LogicMark (OTCMKTS:LGMKD - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends. Analyst Recommendations This is a summary of current ratings
- 2026-09-30 Alphatec CEO Miles Patrick Purchases 115,000 Shares for $1 Million. Is the Medical Tech Stock Now a Buy? Patrick''s purchase brings his total beneficial ownership to 6.2 million shares worth $54.41 million, signaling confidence despite the stock''s 42% decline over the past year.
- 2026-09-23 ATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that Thomas "Tommy" Carls has joined the company as Executive Vice President, Data Intelligence and Strategy. Carls will report directly to Chairman and Chief Executive Officer, Pat Miles, and will serve as a member of ATEC''s Senior Leadership Team. In this newly created role, Carls will lead ATEC''.
- 2026-09-14 Alphatec (ATEC) Moves 19.7% Higher: Will This Strength Last? Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 2026-08-21 Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Recommendation of “Moderate Buy” from Brokerages Alphatec Holdings, Inc. (NASDAQ: ATEC - Get Free Report) has been given an average rating of "Moderate Buy" by the fifteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have assigned a buy recommendation to
- 2026-08-04 Alphatec Holdings, Inc. (ATEC) Q2 2026 Earnings Call Transcript Alphatec Holdings, Inc. (ATEC) Q2 2026 Earnings Call Transcript
- 2026-08-04 Alphatec (ATEC) Q2 Earnings Lag Estimates Alphatec (ATEC) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago.
- 2026-08-04 Alphatec Q2 Earnings Call Highlights Alphatec NASDAQ: ATEC reported second-quarter 2026 revenue of $214 million, up 15% from a year earlier, as growth in surgical procedures and surgeon adoption supported higher profitability and positive free cash flow.
- 2026-08-04 ATEC Reports Second Quarter Financial Results CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended June 30, 2026, and business highlights. Second Quarter 2026 Financial Results Quarter Ended June 30, 2026 Total revenue $214 million GAAP gross margin 72.2% Non-GAAP gross margin 72.5% GAAP operating expenses $156 million Non-GAAP operating expenses $135 mill.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.6% | 69.4% | 64.3% | 66.4% | 64.9% | |
| Ebit Margin | -16.0% | -22.4% | -35.3% | -41.8% | -56.4% | |
| Ebitda Margin | -5.2% | -8.8% | -22.9% | -29.2% | -43.9% | |
| Operating Profit Margin | -10.7% | -22.3% | -36.0% | -41.9% | -52.7% | |
| Pretax Profit Margin | -18.8% | -26.5% | -38.8% | -43.3% | -59.3% | |
| Continuous Operations Profit Margin | -18.8% | -26.5% | -38.7% | -43.1% | -58.8% | |
| Net Profit Margin | -18.8% | -26.5% | -38.7% | -43.1% | -58.8% | |
| Bottom Line Profit Margin | -18.8% | -26.5% | -38.7% | -43.1% | -58.8% | |
| Current Ratio | 2.057 | 2.728 | 2.863 | 1.841 | 3.276 | |
| Quick Ratio | 1.284 | 1.582 | 1.994 | 1.110 | 2.369 | |
| Solvency Ratio | -0.081 | -0.103 | -0.180 | -0.193 | -0.229 | |
| Cash Ratio | 0.734 | 0.907 | 1.402 | 0.610 | 1.852 | |
| Price To Earnings Ratio | -21.917 | -8.124 | -9.812 | -8.401 | -7.747 | |
| Price To Earnings Growth Ratio | 1.457 | 0.305 | -2.060 | 4.201 | -0.286 | |
| Forward Price To Earnings Growth Ratio | 1.457 | 0.305 | -2.060 | 4.201 | -0.286 | |
| Price To Earnings Diluted Ratio | -21.917 | -8.124 | -9.812 | -8.401 | -7.747 | |
| Price To Earnings Diluted Growth Ratio | 1.457 | 0.305 | -2.060 | 4.201 | -0.286 | |
| Price To Book Ratio | 87.633 | 139.097 | 18.010 | -36.826 | 14.074 | |
| Price To Sales Ratio | 4.132 | 2.146 | 3.799 | 3.639 | 4.596 | |
| Price To Free Cash Flow Ratio | 1,137.373 | -9.524 | -11.072 | -9.569 | -7.880 | |
| Price To Operating Cash Flow Ratio | 69.805 | -29.389 | -23.342 | -16.992 | -15.246 | |
| Debt To Assets Ratio | 0.784 | 0.786 | 0.673 | 0.760 | 0.621 | |
| Debt To Equity Ratio | 17.207 | 64.653 | 5.325 | -11.419 | 4.475 | |
| Debt To Capital Ratio | 0.945 | 0.985 | 0.842 | 1.096 | 0.817 | |
| Long Term Debt To Capital Ratio | 0.936 | 0.984 | 0.834 | 1.110 | 0.804 | |
| Financial Leverage Ratio | 21.960 | 82.225 | 7.916 | -15.028 | 7.203 | |
| Working Capital Turnover Ratio | 3.081 | 2.192 | 2.351 | 2.023 | 1.367 | |
| Operating Cash Flow Ratio | 0.206 | -0.292 | -0.498 | -0.541 | -0.725 | |
| Operating Cash Flow Sales Ratio | 0.059 | -0.073 | -0.163 | -0.214 | -0.301 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.061 | 3.086 | 2.108 | 1.776 | 1.935 | |
| Debt Service Coverage Ratio | -0.431 | -2.032 | -5.979 | -4.980 | -14.195 | |
| Interest Coverage Ratio | -3.885 | -5.473 | -10.420 | -26.698 | -18.016 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.639 | -26.963 | -43.410 | -5.026 | -214.377 | |
| Operating Cash Flow Coverage Ratio | 0.073 | -0.073 | -0.145 | -0.190 | -0.206 | |
| Capital Expenditure Coverage Ratio | 1.065 | -0.479 | -0.902 | -1.289 | -1.070 | |
| Dividend Paid And Capex Coverage Ratio | 1.065 | -0.479 | -0.902 | -1.289 | -1.070 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -91.098 | -33.102 | -19.465 | -15.479 | -12.032 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.6% | ▲0.2% | ▲2.7% |
| Ebit Margin | -16.0% | ▲6.4% | ▲18.4% |
| Ebitda Margin | -5.2% | ▲3.6% | ▲16.8% |
| Operating Profit Margin | -10.8% | ▲11.5% | ▲21.9% |
| Pretax Profit Margin | -18.8% | ▲7.7% | ▲18.6% |
| Continuous Operations Profit Margin | -18.8% | ▲7.8% | ▲18.4% |
| Net Profit Margin | -18.8% | ▲7.8% | ▲18.4% |
| Bottom Line Profit Margin | -18.8% | ▲7.8% | ▲18.4% |
| Current Ratio | 2.057 | ▼-0.670 | ▼-0.496 |
| Quick Ratio | 1.284 | ▼-0.298 | ▼-0.384 |
| Solvency Ratio | -0.081 | ▲0.022 | ▲0.077 |
| Cash Ratio | 0.734 | ▼-0.174 | ▼-0.367 |
| Price To Earnings Ratio | -21.917 | ▼-13.793 | ▼-10.717 |
| Price To Earnings Growth Ratio | 1.457 | ▲1.152 | ▲0.734 |
| Forward Price To Earnings Growth Ratio | 1.457 | ▲1.152 | ▲0.734 |
| Price To Earnings Diluted Ratio | -21.917 | ▼-13.793 | ▼-10.717 |
| Price To Earnings Diluted Growth Ratio | 1.457 | ▲1.152 | ▲0.734 |
| Price To Book Ratio | 87.633 | ▼-51.464 | ▲43.236 |
| Price To Sales Ratio | 4.132 | ▲1.986 | ▲0.470 |
| Price To Free Cash Flow Ratio | 1137.373 | ▲1146.896 | ▲917.507 |
| Price To Operating Cash Flow Ratio | 69.805 | ▲99.194 | ▲72.838 |
| Debt To Assets Ratio | 0.783 | ▼-0.003 | ▲0.059 |
| Debt To Equity Ratio | 17.207 | ▼-47.446 | ▲1.159 |
| Debt To Capital Ratio | 0.945 | ▼-0.040 | ▲0.008 |
| Long Term Debt To Capital Ratio | 0.936 | ▼-0.048 | ▲0.002 |
| Financial Leverage Ratio | 21.960 | ▼-60.265 | ▲1.105 |
| Working Capital Turnover Ratio | 3.081 | ▲0.888 | ▲0.878 |
| Operating Cash Flow Ratio | 0.206 | ▲0.498 | ▲0.576 |
| Operating Cash Flow Sales Ratio | 0.059 | ▲0.132 | ▲0.198 |
| Free Cash Flow Operating Cash Flow Ratio | 0.061 | ▼-3.025 | ▼-1.732 |
| Debt Service Coverage Ratio | -0.431 | ▲1.601 | ▲5.092 |
| Interest Coverage Ratio | -3.885 | ▲1.589 | ▲9.014 |
| Short Term Operating Cash Flow Coverage Ratio | 0.639 | ▲27.602 | ▲58.466 |
| Operating Cash Flow Coverage Ratio | 0.073 | ▲0.146 | ▲0.181 |
| Capital Expenditure Coverage Ratio | 1.065 | ▲1.545 | ▲1.600 |
| Dividend Paid And Capex Coverage Ratio | 1.065 | ▲1.545 | ▲1.600 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -91.098 | ▼-57.996 | ▼-56.862 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.16B | $1.31B | $1.83B | $1.28B | $1.12B | |
| Enterprise value | $3.62B | $1.78B | $2.15B | $1.59B | $1.29B | |
| EV / Sales | 4.73x | 2.92x | 4.46x | 4.53x | 5.29x | |
| EV / Op. cash flow | 79.96x | -39.94x | -27.43x | -21.13x | -17.54x | |
| EV / Free cash flow | 1302.77x | -12.94x | -13.01x | -11.90x | -9.06x | |
| EV / EBITDA | -91.10x | -33.10x | -19.46x | -15.48x | -12.03x | |
| Net debt / EBITDA | -11.57x | -8.74x | -2.90x | -3.03x | -1.57x | |
| Current ratio | 2.06x | 2.73x | 2.86x | 1.84x | 3.28x | |
| Income quality | -0.32x | 0.28x | 0.42x | 0.50x | 0.51x | |
| Graham net-net | -$3 | -$3 | -$3 | -$4 | -$2 | |
| Tax burden | 100.0% | 100.0% | 99.9% | 99.5% | 99.2% | |
| Interest burden | 117.3% | 118.1% | 109.8% | 103.8% | 105.2% | |
| Working capital | $231.7M | $264.4M | $293.5M | $116.8M | $230.1M | |
| Invested capital | $566.9M | $620.0M | $645.2M | $377.2M | $467.7M | |
| Return on assets | -18.1% | -20.9% | -23.2% | -29.0% | -25.0% | |
| Operating ROA | -10.5% | -17.2% | -26.1% | -26.9% | -30.6% | |
| Return on tangible assets | -23.0% | -26.5% | -29.6% | -38.7% | -32.0% | |
| Return on equity | -397.9% | -1718.5% | -183.5% | 436.4% | -180.1% | |
| Return on invested capital | -12.8% | -21.6% | -26.4% | -36.4% | -26.7% | |
| Return on capital employed | -14.4% | -21.9% | -26.8% | -38.5% | -27.2% | |
| Earnings yield | -4.5% | -12.4% | -10.2% | -11.9% | -12.8% | |
| Free cash flow yield | 0.1% | -10.5% | -9.0% | -10.5% | -12.7% | |
| Capex / Op. cash flow | 93.9% | -208.6% | -110.8% | -77.6% | -93.5% | |
| Capex / Depreciation | 51.4% | 111.8% | 145.7% | 132.7% | 227.2% | |
| Capex / Sales | 5.6% | 15.2% | 18.0% | 16.6% | 28.2% | |
| SG&A / Sales | 65.2% | 73.6% | 77.6% | 85.5% | 94.3% | |
| R&D / Sales | 10.0% | 13.2% | 14.5% | 12.5% | 13.2% | |
| Stock comp / Sales | 9.6% | 12.0% | 16.8% | 11.6% | 15.0% | |
| Intangibles / Total assets | 21.3% | 21.2% | 21.8% | 25.0% | 21.8% | |
| Days sales outstanding | 46d | 50d | 55d | 62d | 63d | |
| Days payables outstanding | 64d | 103d | 104d | 108d | 110d | |
| Operating cycle | 313d | 391d | 345d | 377d | 455d | |
| Cash conversion cycle | 248d | 288d | 241d | 269d | 345d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years